<DOC>
	<DOCNO>NCT02017964</DOCNO>
	<brief_summary>This phase II trial study well combination chemotherapy work treat young patient newly diagnose , non-metastatic desmoplastic medulloblastoma . Drugs use chemotherapy , vincristine sulfate , cyclophosphamide , methotrexate , etoposide , carboplatin , work different way stop growth tumor cell , either kill cell stop dividing .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Younger Patients With Newly Diagnosed , Non-Metastatic Desmoplastic Medulloblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Estimate progression free survival ( PFS ) distribution patient 0- &lt; 4 year age M0 desmoplastic medulloblastoma ( nodular desmoplastic medulloblastoma extensive nodularity ) treat modified HIT SKK regimen ( exclude use intraventricular methotrexate ) . SECONDARY OBJECTIVES : I . Evaluate feasibility rapid central pathology screen review treatment allocation accord histology assess agreement institutional central pathology review diagnose well among central pathology review diagnosis . II . Prospectively evaluate molecular profile nodular desmoplastic ( ND ) /medulloblastoma extensive nodularity ( MBEN ) medulloblastoma young child . III . Monitor describe neurocognitive adaptive functioning young child ND/MBEN medulloblastoma treat protocol use ALTE07C1 protocol . OUTLINE : INDUCTION THERAPY : Patients receive vincristine sulfate intravenously ( IV ) 1 minute infuse via minibag day 1 , 15 , 29 ; cyclophosphamide IV 1 hour day 1-3 ; methotrexate IV 24 hour day 15 29 ; etoposide IV 60-120 minute day 43-45 ; carboplatin IV 1 hour day 43-45 . Treatment repeat every 63 day 3 course absence disease progression unacceptable toxicity . CONTINUATION THERAPY : Patients receive vincristine sulfate IV 1 minute infuse via minibag day 1 , cyclophosphamide IV 1 hour day 1-3 , etoposide IV 60-120 minute day 21-23 , carboplatin IV 1 hour day 21-23 . Treatment repeat every 42 day 2 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 3 , 6 , 9 , 12 , 16 , 20 , 24 , 36 , 48 , 60 , 72 month .</detailed_description>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Patients must newly diagnose confirm histologic diagnosis nodular desmoplastic ( ND ) medulloblastoma medulloblastoma extensive nodularity ( MBEN ) rapid central pathology screen review ; please note : patient Gorlin syndrome eligible Patient must negative lumbar cerebrospinal fluid ( CSF ) cytology ( lumbar CSF must obtain unless medically contraindicate ) ; CSF cytology stag perform sooner 14 day post operatively , preferably day 14 day 21 allow final staging status enrollment onto study Patients must : Preoperative cranial magnetic resonance imaging ( MRI ) ( recommended gadolinium ) preoperative compute tomography ( CT ) ( recommend contrast ) Postoperative cranial MRI without gadolinium within 72 hour surgery Spinal MRI preop without gadolinium postop without gadolinium within 72 hour surgery Patients must enrol study within 31 day definitive surgical resection time tissue acquire determine diagnosis ; patient must enrol treatment begin ; date protocol therapy project start must later five ( 5 ) calendar day date study enrollment ; patient start protocol therapy Phase II study prior study enrollment consider ineligible Patients must performance status correspond Eastern Cooperative Oncology Group ( ECOG ) score 0 , 1 2 ; use Lansky patient = &lt; 16 year age Patients must life expectancy &gt; = 8 week Patients receive dexamethasone must stable dose least 1 week prior study entry Peripheral absolute neutrophil count ( ANC ) &gt; = 1000/uL Platelet count &gt; = 100,000/uL ( transfusion independent ) Hemoglobin &gt; = 10.0 g/dL ( may receive red blood cell [ RBC ] transfusion ) Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 70 mL/min/1.73 m^2 serum creatinine base age/gender follow : 1 month &lt; 6 month : 0.4 mg/dL 6 month &lt; 1 year : 0.5 mg/dL 1 &lt; 2 year : 0.6 mg/dL 2 &lt; 6 year : 0.8 mg/dL Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) age Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) &lt; 2.5 x upper limit normal ( ULN ) age Central nervous system function define : Patients seizure disorder may enrol anticonvulsant well control Patients must status , coma assist ventilation prior study enrollment Patients metastatic disease either MRI evaluation ( brain spine ) lumbar CSF cytology eligible Patients must receive prior tumordirected therapy surgical intervention corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>47 Months</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>